<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186290</url>
  </required_header>
  <id_info>
    <org_study_id>BMT34</org_study_id>
    <secondary_id>74165</secondary_id>
    <secondary_id>BMT34</secondary_id>
    <nct_id>NCT00186290</nct_id>
  </id_info>
  <brief_title>Allo BMT in Advanced Leukemia or High Grade Lymphoma</brief_title>
  <official_title>Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the
      treatment of advanced leukemia or lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the disease free survival and overall survival of patients with ALL and ANLL
      after induction failure, in relapse, or subsequent remission from CML in several phases or
      recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide
      followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated
      Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by
      Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade
      Lymphoma
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1989</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>october 2009</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>disease free survival</measure>
    <time_frame>October 2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>early and late toxicities of the treatment regimen</measure>
    <time_frame>October 2009</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Leukemia</condition>
  <condition>Blood and Marrow Transplant (BMT)</condition>
  <condition>Lymphomas: Non-Hodgkin</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ablative allogeneic hematopoietic cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:HLA identical donor

          -  adequate organ function

          -  other life threatening disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Lowsky</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>October 7, 2010</last_update_submitted>
  <last_update_submitted_qc>October 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert Lowsky</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

